May 2015 $50 M No. 5 $50 to $250 million 5
Sprout Pharmaceuticals, Inc.: Raise no. 5, May 2015 × Investors in this round 5 investors had bought by the notice of Jun 8, 2015: 5 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $50 M of $50 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Anne S. Tomalin · Executive Officer · Vice President, Global Regulatory Affairs Cynthia Whitehead · Executive Officer, Director · Director, President and Chief Executive Officer Douglas S. Eckert · Executive Officer, Director · Director, Secretary James S. Pruden · Executive Officer · Vice President, Manufacturing Josephine S. Torrente · Executive Officer · Executive Vice President, Corporate and Regulatory Affairs Matthew S. Petzold · Executive Officer · Chief Financial Officer and Treasurer Rich S. Franco · Executive Officer · Executive Vice President, Strategy Robert S. Whitehead · Executive Officer, Director · Director, Executive Director Anthony S. Wild · Director Braxton Robert Goodrich · Director Michael Robert Ford · Director Richard Robert DeSchutter · Director Trygve Robert Mikkelsen · Director W. Robert Dahl · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “The proceeds from the offering will be used for working capital purposes, of which a portion may be used to pay the salaries of the Company's executive officers.”Signed by Matthew Petzold, Chief Financial Officer and Treasurer. Source: SEC Form D, newest notice filed Jun 8, 2015. Read the notice at the SEC .
equity SEC Jun 2014 $4 M No. 4 $2 to $10 million 69
Sprout Pharmaceuticals, Inc.: Raise no. 4, Jun 2014 × Investors in this round 69 investors had bought by the notice of Jul 11, 2014: 69 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $4 M of $15 M offered; $11 M still to sell
Smallest investment taken $50,000
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Anne S Tomalin · Executive Officer · Acting Vice President, Global Regulatory Affairs Cynthia S Whitehead · Executive Officer, Director · Director, President and Chief Operating Officer Douglas W. Eckert · Executive Officer, Director · Director and Secretary James S Pruden · Executive Officer · Vice President, Manufacturing Matthew S Petzold · Executive Officer · Chief Financial Officer and Treasurer Robert S Whitehead · Executive Officer, Director · Director, Chief Executive Officer Anthony S Wild · Director Braxton W. Goodrich · Director Michael W. Ford · Director Richard W. DeSchutter · Director Robert W. Dahl · Director Trygve W. Mikkelsen · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “The proceeds from the offering will be used for working capital purposes, of which a portion may be used to pay the salaries of the Company's executive officers.”Signed by Matthew Petzold, Chief Financial Officer and Treasurer. Source: SEC Form D, newest notice filed Jul 11, 2014. Read the notice at the SEC .
equity SEC Jun 2013 $10 M No. 3 $10 to $50 million 88
Sprout Pharmaceuticals, Inc.: Raise no. 3, Jun 2013 × Investors in this round 88 investors had bought by the notice of Jul 26, 2013: 88 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $10 M of $10 M offered
Smallest investment taken $50,000
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Cynthia S. Whitehead · Executive Officer · Chief Operating Officer Douglas S. Eckert · Executive Officer, Director · Director and Secretary Fred S. Pruden · Executive Officer · Vice President, Manufacturing James Robert Symons · Executive Officer · Vice President, Drug Development Matthew S. Petzold · Executive Officer · Chief Financial Officer and Treasurer Robert S. Whitehead · Executive Officer, Director · Director, President and Chief Executive Officer Anthony Robert Wild · Director Braxton Robert Goodrich · Director Michael Robert Ford · Director Richard Robert DeSchutter · Director Trygve Robert Mikkelsen · Director W. Robert Dahl · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “The proceeds from the offering will be used for working capital purposes, of which a portion may be used to pay the salaries of the Issuer's executive officers.”Signed by Matthew Petzold, Chief Financial Officer and Treasurer. Source: SEC Form D and 1 amendment, newest notice filed Jul 26, 2013. Read the notice at the SEC .
equity SEC Jun 2012 $20 M No. 2 $10 to $50 million 59
Sprout Pharmaceuticals, Inc.: Raise no. 2, Jun 2012 × Investors in this round 59 investors had bought by the notice of Jul 11, 2012: 59 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $20 M of $20 M offered
Smallest investment taken $50,000
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Cynthia S. Whitehead · Executive Officer · Chief Operating Officer Douglas S. Eckert · Executive Officer, Director · Director and Secretary Fred S. Pruden · Executive Officer · Vice President, Manufacturing James Robert Symons · Executive Officer · Vice President, Drug Development Matthew S. Petzold · Executive Officer · Chief Financial Officer and Treasurer Robert S. Whitehead · Executive Officer, Director · Director, President and Chief Executive Officer Anthony Robert Wild · Director Braxton Robert Goodrich · Director Michael Robert Ford · Director Richard Robert DeSchutter · Director Trygve Robert Mikkelsen · Director W. Robert Dahl · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “The proceeds from the offering will be used for working capital purposes, of which a portion may be used to pay the salaries of the Issuer's executive officers.”Signed by Matthew Petzold, Chief Financial Officer and Treasurer. Source: SEC Form D and 1 amendment, newest notice filed Jul 11, 2012. Read the notice at the SEC .
equity SEC Mar 2012 $5 M No. 1 $2 to $10 million 61
Sprout Pharmaceuticals, Inc.: Raise no. 1, Mar 2012 × Investors in this round 61 investors had bought by the notice of Mar 21, 2012: 61 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $5 M of $5 M offered
Smallest investment taken $50,000
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Cynthia S. Whitehead · Executive Officer · Chief Commercial Officer Douglas S. Eckert · Executive Officer, Director · Director and Secretary Fred S. Pruden · Executive Officer · Vice President, Manufacturing James Robert Symons · Executive Officer · Vice President, Drug Development Matthew S. Petzold · Executive Officer · Chief Financial Officer and Treasurer Robert S. Whitehead · Executive Officer, Director · Director, President and Chief Executive Officer Anthony Robert Wild · Director Braxton Robert Goodrich · Director Michael Robert Ford · Director Richard Robert DeSchutter · Director Trygve Robert Mikkelsen · Director W. Robert Dahl · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “The Board of Directors of the Issuer may, in its discretion, increase the aggregate offering amount to $6,000,000.”On the use of proceeds: “The Proceeds will be used for working capital purposes, of which a portion will be used to pay the salaries of the Issuer's executive officers.”Signed by Matthew Petzold, Chief Financial Officer. Source: SEC Form D, newest notice filed Mar 21, 2012. Read the notice at the SEC .
equity SEC